Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

被引：195

作者：

Casali, P. G. ^{[1
]}

Blay, J. -Y. ^{[2
,3
]}

机构：

[1] Ist Nazl Tumori, Dept Canc Med, I-20133 Milan, Italy

[2] Hop Edouard Herriot, Dept Oncol, Lyon, France

[3] Univ Lyon 1, INSERM, U590, F-69365 Lyon, France

来源：

ANNALS OF ONCOLOGY | 2010年 / 21卷

关键词：

PHASE-II TRIAL; IMATINIB MESYLATE; ADVANCED/METASTATIC GIST; DOSE IMATINIB; SARCOMA-GROUP; RESECTION; KIT; PROGRESSION; THERAPY; SURGERY;

D O I：

10.1093/annonc/mdq208

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：v98 / v102

页数：5

共 26 条

[1] We should desist using RECIST, at least in GIST [J].

Benjamin, Robert S. ;

Choi, Haesun ;

Macapinlac, Homer A. ;

Burgess, Michael A. ;

Patel, Shreyaskumar R. ;

Chen, Lei L. ;

Podoloff, Donald A. ;

Charnsangavej, Chuslip .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1760-1764

[2] Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT [J].

Blanke, Charles D. ;

Demetri, George D. ;

von Mehren, Margaret ;

Heinrich, Michael C. ;

Eisenberg, Burton ;

Fletcher, Jonathan A. ;

Corless, Christopher L. ;

Fletcher, Christopher D. M. ;

Roberts, Peter J. ;

Heinz, Daniela ;

Wehre, Elisabeth ;

Nikolova, Zariana ;

Joensuu, Heikki .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :620-625

[3] Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 [J].

Blanke, Charles D. ;

Rankin, Cathryn ;

Demetri, George D. ;

Ryan, Christopher W. ;

von Mehren, Margaret ;

Benjamin, Robert S. ;

Raymond, A. Kevin ;

Bramwell, Vivien H. C. ;

Baker, Laurence H. ;

Maki, Robert G. ;

Tanaka, Michael ;

Hecht, J. Randolph ;

Heinrich, Michael C. ;

Fletcher, Christopher D. M. ;

Crowley, John J. ;

Borden, Ernest C. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :626-632

[4]

Blay JY, 2007, J CLIN ONCOL, V25, P1107, DOI 10.1200/JCO.2006.09.0183

[5] KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours [J].

Debiec-Rychter, Maria ;

Sciot, Raf ;

Le Cesne, Axel ;

Schlemmer, Marcus ;

Hohenberger, Peter ;

van Oosterom, Allan T. ;

Blay, Jean-Yves ;

Leyvraz, Serge ;

Stul, Michel ;

Casali, Paolo G. ;

Zalcberg, John ;

Verweij, Jaap ;

Van Glabbeke, Martine ;

Hagemeijer, Anne ;

Judson, Ian .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (08) :1093-1103

[6] Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) [J].

DeMatteo, Ronald P. ;

Gold, Jason S. ;

Saran, Lisa ;

Goenen, Mithat ;

Liau, Kui Hin ;

Maki, Robert G. ;

Singer, Samuel ;

Besmer, Peter ;

Brennan, Murray F. ;

Antonescu, Cristina R. .

CANCER, 2008, 112 (03) :608-615

[7] Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial [J].

DeMatteo, Ronald P. ;

Ballman, Karla V. ;

Antonescu, Cristina R. ;

Maki, Robert G. ;

Pisters, Peter W. T. ;

Demetri, George D. ;

Blackstein, Martin E. ;

Blanke, Charles D. ;

von Mehren, Margaret ;

Brennan, Murray F. ;

Patel, Shreyaskumar ;

McCarter, Martin D. ;

Polikoff, Jonathan A. ;

Tan, Benjamin R. ;

Owzar, Kouros .

LANCET, 2009, 373 (9669) :1097-1104

[8] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].

Demetri, GD ;

von Mehren, M ;

Blanke, CD ;

Van den Abbeele, AD ;

Eisenberg, B ;

Roberts, PJ ;

Heinrich, MC ;

Tuveson, DA ;

Singer, S ;

Janicek, M ;

Fletcher, JA ;

Silverman, SG ;

Silberman, SL ;

Capdeville, R ;

Kiese, B ;

Peng, B ;

Dimitrijevic, S ;

Druker, BJ ;

Corless, C ;

Fletcher, CDM ;

Joensuu, H .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480

[9] Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial [J].

Demetri, George D. ;

van Oosterom, Allan T. ;

Garrett, Christopher R. ;

Blackstein, Martin E. ;

Shah, Manisha H. ;

Verweij, Jaap ;

McArthur, Grant ;

Judson, Ian R. ;

Heinrich, Michael C. ;

Morgan, Jeffrey A. ;

Desai, Jayesh ;

D Fletcher, Christopher ;

George, Suzanne ;

Bello, Carlo L. ;

Huang, Xin ;

Baum, Charles M. ;

Casali, Paolo G. .

LANCET, 2006, 368 (9544) :1329-1338

[10] Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors [J].

Demetri, George D. ;

Wang, Yanfeng ;

Wehrle, Elisabeth ;

Racine, Amy ;

Nikolova, Zariana ;

Blanke, Charles D. ;

Joensuu, Heikki ;

von Mehren, Margaret .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3141-3147

← 1 2 3 →